About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.

Northern Survey on Therapeutic Oxygen Prescription

Clinicaltrials.gov identifier NCT03937622

Recruitment Status Recruiting

First Posted May 6, 2019

Last update posted August 7, 2019

Study Description

Brief summary:

This is a prospective multicenter observational trial. Included patients and attending physician complete a standardized questionnaire.

  • Condition or Disease:Oxygen Toxicity
  • Intervention/Treatment: Other: 17 items questionaire
  • Phase: N/A
Detailed Description

N/A

Study Design
  • Study Type: Observational
  • Estimated Enrollment: 500 participants
  • Observational Model: Cohort
  • Time Perspective: Prospective
  • Official Title: Northern Survey on Therapeutic Oxygen Prescription
  • Actual Study Start Date: July 2019
  • Estimated Primary Completion Date: June 2021
  • Estimated Study Completion Date: September 2021
Outcome Measures
  • Primary Outcome Measures: 1. Validation of indication of Long-term Oxygen therapy (LTOT) [ Time Frame: 12 month ]
    Aim of this study is to observe the real-world handling with longterm Oxygen treatment in northern Germany
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
  • Sampling Method: Non-Probability Sample
  • Study Population: Patients fulfilling the Inclusion criteria and not the exclusion criteria at 3 Centers in nothern Germany
Criteria

Inclusion Criteria:

- Patients with chronic lung disease, age > 18 years

- Established domiciliary LTOT > 4 weeks

- Scheduled for control of oxygen therapy with arterial/capillary

Exclusion Criteria:

- No informed consent

- Pulmonary exacerbation within the last 2 weeks

- Signs of heart failure (edema, congestion)

Contacts and Locations
Contacts

Contact: Thomas Fühner, PD Dr. med. +49 531595 ext 431 fühner.thomas@mh-hannover.de

Contact: Heiko Golpon, PD Dr. med. +49 511 532 ext 6553 golpon.heiko@mh-hannover.de

Locations

Germany
Dep. Respiratory Medicine, Hannover Medical School
Hannover

Germany
Department of Respiratory Medicine, Medizinische Hochschule Hannover
Hannover

Sponsors and Collaborators

Hannover Medical School

Investigators

Principal Investigator: Jens Gottlieb, Prof. Dr. med. Hannover Medical School

More Information
  • Responsible Party: Hannover Medical School
  • ClinicalTrials.gov Identifier: NCT03937622 History of Changes
  • Other Study ID Numbers: Pneumo-O2
  • First Posted: May 6, 2019 Key Record Dates
  • Last Update Posted: August 7, 2019
  • Last Verified: August 2019
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Plan Description: No sharing of individual participants data
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No